Great frist results from $CRIS_老虎社区_美港股上老虎

Ares_M
2021-06-12

Great frist results from $CRISPR Therapeutics AG(CRSP)$& $Vertex(VTNR)$study on gen editing therapy to cure Thalssemia.

CRSP is a clear win for 5y+ investors and has a massive growth ahead for the next 10 years, as a Biologist I can't but agree on the 9X figures.

“This approach uses CRISPR/Cas9 gene editing to enable the patient’s own cells to produce fetal hemoglobin, and to see results that demonstrate the potential for a treatment that may transform the lives of many patients is an exciting time for me and the team.”

https://www.businesswire.com/news/home/20210611005069/en/Vertex-and-CRISPR-Therapeutics-Present-New-Data-in-22-Patients-With-Greater-Than-3-Months-Follow-Up-Post-Treatment-With-Investigational-CRISPRCas9-Gene-Editing-Therapy-CTX001%E2%84%A2-at-European-Hematology-Association-Annual-Meeting

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":186017642,"tweetId":"186017642","gmtCreate":1623465140386,"gmtModify":1631883938143,"author":{"id":3576575729067569,"authorId":3576575729067569,"authorIdStr":"3576575729067569","name":"Ares_M","avatar":"https://static.tigerbbs.com/491b8c393aef71494a2e01a221f50bbc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Great frist results from&nbsp;<a href=\"https://laohu8.com/S/CRSP\">$CRISPR Therapeutics AG(CRSP)$</a>&amp; <a href=\"https://laohu8.com/S/VTNR\">$Vertex(VTNR)$</a>study on gen editing therapy to cure Thalssemia.CRSP is a clear win for 5y+ investors and&nbsp;has a massive growth ahead for the next 10 years, as a Biologist I can't but agree on the 9X figures.“This approach uses CRISPR/Cas9 gene editing to enable the patient’s own cells to produce fetal hemoglobin, and to see results that demonstrate the potential for a treatment that may transform the lives of many patients is an exciting time for me and the team.”https://www.businesswire.com/news/home/20210611005069/en/Vertex-and-CRISPR-Therapeutics-Present-New-Data-in-22-Patients-With-Greater-Than-3-Months-Follow-Up-Post-Treatment-With-Investigational-CRISPRCas9-Gene-Editing-Therapy-CTX001%E2%84%A2-at-European-Hematology-Association-Annual-Meeting</body></html>","htmlText":"<html><head></head><body>Great frist results from&nbsp;<a href=\"https://laohu8.com/S/CRSP\">$CRISPR Therapeutics AG(CRSP)$</a>&amp; <a href=\"https://laohu8.com/S/VTNR\">$Vertex(VTNR)$</a>study on gen editing therapy to cure Thalssemia.CRSP is a clear win for 5y+ investors and&nbsp;has a massive growth ahead for the next 10 years, as a Biologist I can't but agree on the 9X figures.“This approach uses CRISPR/Cas9 gene editing to enable the patient’s own cells to produce fetal hemoglobin, and to see results that demonstrate the potential for a treatment that may transform the lives of many patients is an exciting time for me and the team.”https://www.businesswire.com/news/home/20210611005069/en/Vertex-and-CRISPR-Therapeutics-Present-New-Data-in-22-Patients-With-Greater-Than-3-Months-Follow-Up-Post-Treatment-With-Investigational-CRISPRCas9-Gene-Editing-Therapy-CTX001%E2%84%A2-at-European-Hematology-Association-Annual-Meeting</body></html>","text":"Great frist results from $CRISPR Therapeutics AG(CRSP)$& $Vertex(VTNR)$study on gen editing therapy to cure Thalssemia. CRSP is a clear win for 5y+ investors and has a massive growth ahead for the next 10 years, as a Biologist I can't but agree on the 9X figures. “This approach uses CRISPR/Cas9 gene editing to enable the patient’s own cells to produce fetal hemoglobin, and to see results that demonstrate the potential for a treatment that may transform the lives of many patients is an exciting time for me and the team.” https://www.businesswire.com/news/home/20210611005069/en/Vertex-and-CRISPR-Therapeutics-Present-New-Data-in-22-Patients-With-Greater-Than-3-Months-Follow-Up-Post-Treatment-With-Investigational-CRISPRCas9-Gene-Editing-Therapy-CTX001%E2%84%A2-at-European-Hematology-Association-Annual-Meeting","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/186017642","repostId":0,"isVote":1,"tweetType":1,"viewCount":547,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["CRSP","VTNR"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":727,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}